Human papillomavirus 16 E7 protein inhibits interferon-γ-mediated enhancement of keratinocyte antigen processing and T-cell lysis

FEBS Journal

Volumn 278, Issue 6, 2011, Pages 955-963

  Zhou, Fang ^a   Leggatt, Graham R ^a   Frazer, Ian H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

antigen processing; CD8 T cells; host virus interactions; papillomavirus

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN; OVALBUMIN; PROTEIN E7; PROTEIN H2KB; PROTEIN SIINFEKL; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOLYSIS; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION;

ANIMALS; ANTIGEN PRESENTATION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-GAMMA; KERATINOCYTES; MICE; PAPILLOMAVIRUS E7 PROTEINS; T-LYMPHOCYTES;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS - 16; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 79952518044     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08011.x     Document Type: Article

References (41)

1. Koshiol JE, Schroeder JC, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, Shah KV, Klein RS, Cuuvin S, &, Schuman P, (2006) Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 119, 1623-1629. (Pubitemid 44258768)
2. Kanodia S, Fahey LM, &, Kast WM, (2007) Mechanisms used by human papillomaviruses to escape the host immune response. Curr Cancer Drug Targets 7, 79-89. (Pubitemid 46345510)
3. Dunn LA, Evander M, Tindle RW, Bulloch AL, De Kluyver RL, Fernando GJ, Lambert PF, &, Frazer IH, (1997) Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal. Virology 235, 94-103. (Pubitemid 27380809)
4. Azukizawa H, Kosaka H, Sano S, Heath WR, Takahashi I, Gao XH, Sumikawa Y, Okabe M, Yoshikawa K, &, Itami S, (2003) Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes. Eur J Immunol 33, 1879-1888. (Pubitemid 37120859)
5. Leggatt GR, Dunn LA, De Kluyver R, Stewart T, &, Frazer IH, (2002) Interferon-gamma enhances cytotoxic T lymphocyte recognition of endogenous peptide in keratinocytes without lowering the requirement for surface peptide. Immunol Cell Biol 80, 415-424.
6. Zhou F, Frazer IH, &, Leggatt GR, (2009) Keratinocytes efficiently process endogenous antigens for cytotoxic T-cell mediated lysis. Exp Dermatol 18, 1053-1059.
7. Georgopoulos NT, Proffitt JL, &, Blair GE, (2000) Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins. Oncogene 19, 4930-4935.
8. Evans M, Borysiewicz LK, Evans AS, Rowe M, Jones M, Gileadi U, Cerundolo V, &, Man S, (2001) Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. J Immunol 167, 5420-5428. (Pubitemid 33009783)
9. Thomas KJ, Smith KL, Youde SJ, Evans M, Fiander AN, Borysiewicz LK, &, Man S, (2008) HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function. Int J Cancer 122, 2791-2799. (Pubitemid 351631382)
10. Hill A, Jugovic P, York I, Russ G, Bennink J, Yewdell J, Ploegh H, &, Johnson D, (1995) Herpes simplex virus turns off the TAP to evade host immunity. Nature 375, 411-415.
11. Levitskaya J, Coram M, Levitsky V, Imreh S, Steigerwald-Mullen PM, Klein G, Kurilla MG, &, Masucci MG, (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375, 685-688.
12. Ahn K, Meyer TH, Uebel S, Sempé P, Djaballah H, Yang Y, Peterson PA, Fruh K, &, Tamp R, (1996) Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus protein ICP47. EMBO J 15, 3247-3255. (Pubitemid 26231930)
13. Ahn K, Gruhler A, Galocha B, Jones TR, Wiertz EJ, Ploegh HL, Peterson PA, Yang Y, &, Fruh K, (1997) The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity 6, 613-621. (Pubitemid 27239352)
14. Boehm U, Klamp T, Groot M, &, Howard JC, (1997) Cellular responses to interferon-gamma. Annu Rev Immunol 15, 749-795.
15. Seresini S, Origoni M, Lillo F, Caputo L, Paganoni AM, Vantini S, Longhi R, Taccagni G, Ferrari A, Doglioni C, Secchi P, &, Protti MP, (2007) IFN-gamma produced by human papilloma virus-18 E6-specific CD4 + T cells predicts the clinical outcome after surgery in patients with high-grade cervical lesions. J Immunol 179, 7176-7183.
16. Barnard P, &, McMillan NAJ, (1999) The human papillomavirus E7 oncoprotein abrogates signaling mediated by interferon-α. Virology 259, 305-313. (Pubitemid 29393381)
17. Chang YE, &, Laimins LA, (2000) Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 74, 4174-4182. (Pubitemid 30214423)
18. Koromilas AE, Li S, &, Matlashewski G, (2001) Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev 12, 157-170. (Pubitemid 32588142)
19. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, &, Woodworth CD, (2001) Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J Virol 75, 4283-4296. (Pubitemid 32410141)
20. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, &, Um SJ, (2000) Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein-implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 275, 6764-6769.
21. Um SJ, Rhyu JW, Kim EJ, Jeon KC, Hwang ES, &, Park JS, (2002) Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett 179, 205-212.
22. Niederwieser D, Aubock J, Troppmair J, Herold M, Schuler G, Boeck G, Lotz J, Fritsch P, &, Huber C, (1988) IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses. J Immunol 140, 2556-2564.
23. Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, &, Campo MS, (2005) E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer 113, 276-283. (Pubitemid 39628318)
24. Vambutas A, DeVoti J, Pinn W, Steinberg BM, &, Bonagura VR, (2001) Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin Immunol 101, 94-99.
25. Park JS, Boyer S, Mitchell K, Gilfor D, Birrer M, Darlington G, El Deiry W, Firestone GL, Munger K, Band V, Fisher PB, &, Dent P, (2000) Expression of human papilloma virus E7 protein causes apoptosis and inhibits DNA synthesis in primary hepatocytes via increased expression of p21Cip-1/WAF1/MDA6. J Biol Chem 275, 18-28. (Pubitemid 30038947)
26. Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, &, Seliger B, (2001) Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19, 1211-1220.
27. Tennant LM, Renard C, Chardon P, &, Powell PP, (2007) Regulation of porcine classical and nonclassical MHC class I expression. Immunogenetics 59, 377-389. (Pubitemid 46537507)
28. Briscoe J, Guschin D, Rogers NC, Watling D, Muller M, Horn F, Heinrich P, Stark GR, &, Kerr IM, (1996) JAKs, STATs and signal transduction in response to the interferons and other cytokines. Phil Trans R Soc Lond B Biol Sci 351, 167-171. (Pubitemid 126745326)
29. Cordano P, Gillan V, Bratlie S, Bouvard V, Banks L, Tommasino M, &, Campo MS, (2008) The E6E7 oncoproteins of cutaneous human papillomavirus type 38 interfere with the interferon pathway. Virology 377, 408-418.
30. Li SY, Labrecque S, Gauzzi MC, Cuddihy AR, Wong AHT, Pellegrini S, Matlashewski GJ, &, Koromilas AE, (1999) The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-α. Oncogene 18, 5727-5737. (Pubitemid 29507426)
31. Perea SE, Massimi P, &, Banks L, (2000) Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1. Int J Mol Med 5, 661-666.
32. Frazer IH, (2004) Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4, 46-55.
33. Frazer IH, &, Appleton S, (2006) Vaccines to prevent and treat human papillomavirus associated anogenital disease. In The Cervix, 2nd edn (, Jordan JA, &, Singer A, eds), pp. 609-620. Blackwell Publishing, Oxford.
34. Wang RF, Miyahara Y, &, Wang HY, (2008) Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 27, 181-189.
35. Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, &, Koyasu S, (2001) IFN-gamma-production by antigen-presenting cells: mechanisms emerge. Immunol Today 22, 556-560. (Pubitemid 33016402)
36. Frazer IH, &, McMillan NA, (1997) Papillomatosis and condylomata acuminata. In Clinical Applications of the Interferons (, Stuart-Harris R, &, Penny RW, eds), pp. 79-91. Chapman and Hall Medical, London.
37. Stefanski HE, Mayerova D, Jameson SC, &, Hogquist KA, (2001) A low affinity TCR ligand restores positive selection of CD8 + T cells in vivo. J Immunol 166, 6602-6607. (Pubitemid 32467200)
38. Herber R, Liem A, Pitot H, &, Lambert PF, (1996) Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol 70, 1873-1881. (Pubitemid 26062951)
39. Moore MW, Carbone FR, &, Bevan MJ, (1988) Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54, 777-785.
40. Carbone FR, &, Bevan MJ, (1990) Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J Exp Med 171, 377-387. (Pubitemid 20059033)
41. Porgador A, Yewdell JW, Deng Y, Bennink JR, &, Germain RN, (1997) Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6, 715-726. (Pubitemid 27305734)